A review of Dengvaxia®: development to deployment

Long-term immunogenicity and safety of tetravalent dengue vaccine (CYD-TDV) in healthy populations in Singapore and Vietnam: 4-year follow-up of randomized, controlled, phase II trials

(2019) Ngoc Huu Tran et al.   Human Vaccines & Immunotherapeutics

Dengue Vaccine Booster in Healthy Adolescents and Adults in Latin America

(2019) Diana Coronel et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Onchocerca - infected cattle produce strong antibody responses to excretory-secretory proteins released from adult male Onchocerca ochengi worms

(2018) Djafsia Boursou et al.   BMC INFECTIOUS DISEASES

Four-year safety follow-up of the tetravalent dengue vaccine efficacy randomized controlled trials in Asia and Latin America

(2018) J.L. Arredondo-García et al.   CLINICAL MICROBIOLOGY AND INFECTION

Development of an anti-dengue NS1 IgG ELISA to evaluate exposure to dengue virus

(2018) Eduardo J.M. Nascimento et al.   JOURNAL OF VIROLOGICAL METHODS

Improvement of the Dengue Virus (DENV) Nonhuman Primate Model via a Reverse Translational Approach Based on Dengue Vaccine Clinical Efficacy Data against DENV-2 and -4

(2018) Veronique Barban et al.   JOURNAL OF VIROLOGY

The dynamic role of dengue cross-reactive immunity: changing the approach to defining vaccine safety and efficacy

(2018) Kathryn B Anderson et al.   LANCET INFECTIOUS DISEASES

Effect of Dengue Serostatus on Dengue Vaccine Safety and Efficacy

(2018) Saranya Sridhar et al.   NEW ENGLAND JOURNAL OF MEDICINE

Characterization of recombinant yellow fever-dengue vaccine viruses with human monoclonal antibodies targeting key conformational epitopes

(2018) Valerie Lecouturier et al.   VACCINE

Evaluation of Interferences between Dengue Vaccine Serotypes in a Monkey Model

(2018) Bruno Guy et al.   AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE

Reconstruction of antibody dynamics and infection histories to evaluate dengue risk

(2018) Henrik Salje et al.   NATURE

Viral genetic diversity and protective efficacy of a tetravalent dengue vaccine in two phase 3 trials

(2018) Michal Juraska et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Safety Follow-up of a Dengue Vaccine When Administered Concomitantly with a Yellow Fever Vaccine in Healthy Toddlers in Colombia

(2018) Margarita Cortés et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Dengue vaccine: WHO position paper, September 2018 – Recommendations

(2018)   VACCINE

Protective versus pathologic pre-exposure cytokine profiles in dengue virus infection

(2018) Heather Friberg et al.   PLoS Neglected Tropical Diseases

Quantification of dengue virus specific T cell responses and correlation with viral load and clinical disease severity in acute dengue infection

(2018) Dulharie T. Wijeratne et al.   PLoS Neglected Tropical Diseases

Pathogenesis of vascular leak in dengue virus infection

(2017) Gathsaurie Neelika Malavige et al.   IMMUNOLOGY

Neutralizing Antibody Correlates Analysis of Tetravalent Dengue Vaccine Efficacy Trials in Asia and Latin America

(2017) Zoe Moodie et al.   JOURNAL OF INFECTIOUS DISEASES

Replication and Excretion of the Live Attenuated Tetravalent Dengue Vaccine CYD-TDV in a Flavivirus-Naive Adult Population: Assessment of Vaccine Viremia and Virus Shedding

(2017) Joseph Torresi et al.   JOURNAL OF INFECTIOUS DISEASES

Immunogenicity and Safety of a Booster Injection of DTap-IPV//Hib (Pentaxim) Administered Concomitantly With Tetravalent Dengue Vaccine in Healthy Toddlers 15–18 Months of Age in Mexico

(2017) Flor Irene Rodriguez Melo et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Immune-mediated cytokine storm and its role in severe dengue

(2017) Anon Srikiatkhachorn et al.   Seminars in Immunopathology

Biodistribution and safety of a live attenuated tetravalent dengue vaccine in the cynomolgus monkey

(2017) Guillaume Ravel et al.   VACCINE

Integrated immunogenicity analysis of a tetravalent dengue vaccine up to 4 y after vaccination

(2017) Claire Vigne et al.   Human Vaccines & Immunotherapeutics

Genetic epidemiology of dengue viruses in phase III trials of the CYD tetravalent dengue vaccine and implications for efficacy

(2017) Maia A Rabaa et al.   eLife

Dissecting antibodies induced by a chimeric yellow fever-dengue, live-attenuated, tetravalent dengue vaccine (CYD-TDV) in naïve and dengue exposed individuals

(2016) Sandra Henein et al.   JOURNAL OF INFECTIOUS DISEASES

Tetravalent Dengue Vaccine Reduces Symptomatic and Asymptomatic Dengue Virus Infections in Healthy Children and Adolescents Aged 2–16 Years in Asia and Latin America

(2016) Gustavo Olivera-Botello et al.   JOURNAL OF INFECTIOUS DISEASES

Immunogenicity and Safety of Yellow Fever Vaccine (Stamaril) When Administered Concomitantly With a Tetravalent Dengue Vaccine Candidate in Healthy Toddlers at 12–13 Months of Age in Colombia and Peru

(2016) Pio López et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Neutralizing antibody titers against dengue virus correlate with protection from symptomatic infection in a longitudinal cohort

(2016) Leah C. Katzelnick et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Low antibody titers 5 years after vaccination with the CYD-TDV dengue vaccine in both pre-immune and naïve vaccinees

(2016) Sumathy Velumani et al.   Human Vaccines & Immunotherapeutics

Immune Response to Dengue Virus Infection in Pediatric Patients in New Delhi, India—Association of Viremia, Inflammatory Mediators and Monocytes with Disease Severity

(2016) Mohit Singla et al.   PLoS Neglected Tropical Diseases

Binational Dengue Outbreak Along the United States–Mexico Border — Yuma County, Arizona, and Sonora, Mexico, 2014

(2016) Jefferson M. Jones et al.   MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT

Dengue infection

(2016) Maria G. Guzman et al.   Nature Reviews Disease Primers

Trials and Tribulations on the Path to Developing a Dengue Vaccine

(2015) Stephen J. Thomas et al.   AMERICAN JOURNAL OF PREVENTIVE MEDICINE

Dengue

(2015) Maria G Guzman et al.   LANCET

Dengue vaccine: hypotheses to understand CYD-TDV-induced protection

(2015) Bruno Guy et al.   NATURE REVIEWS MICROBIOLOGY

Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease

(2015) Sri Rezeki Hadinegoro et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy of a Tetravalent Dengue Vaccine in Children in Latin America

(2015) Luis Villar et al.   NEW ENGLAND JOURNAL OF MEDICINE

First Experience of Concomitant Vaccination Against Dengue and MMR in Toddlers

(2015) Denis Crevat et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Modelling the immunological response to a tetravalent dengue vaccine from multiple phase-2 trials in Latin America and South East Asia

(2015) Ilaria Dorigatti et al.   VACCINE

Site-specific characterization of envelope protein N-glycosylation on Sanofi Pasteur's tetravalent CYD dengue vaccine

(2015) Jean Dubayle et al.   VACCINE

Development of the Sanofi Pasteur tetravalent dengue vaccine: One more step forward

(2015) Bruno Guy et al.   VACCINE

Lot-to-lot consistency of a tetravalent dengue vaccine in healthy adults in Australia: A randomised study

(2015) Joseph Torresi et al.   VACCINE

Immunogenicity and safety of a tetravalent dengue vaccine in healthy adults in India: A randomized, observer-blind, placebo-controlled phase II trial

(2015) Anand Prakash Dubey et al.   Human Vaccines & Immunotherapeutics

Epidemiology of Infant Dengue Cases Illuminates Serotype-Specificity in the Interaction between Immunity and Disease, and Changes in Transmission Dynamics

(2015) Hannah Clapham et al.   PLoS Neglected Tropical Diseases

Proteomic analysis of immunogenic proteins from salivary glands of Aedes aegypti

(2015) Rike Oktarianti et al.   Journal of Infection and Public Health

Developing a dengue vaccine: progress and future challenges

(2014) Stephen J. Thomas   Annals of the New York Academy of Sciences

Differential clinical symptoms among acute phase Indian patients revealed significant association with dengue viral load and serum IFN-gamma level

(2014) Tithi Pal et al.   JOURNAL OF CLINICAL VIROLOGY

Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial

(2014) Maria Rosario Capeding et al.   LANCET

Assessment of bivalent and tetravalent dengue vaccine formulations in flavivirus-naïve adults in Mexico

(2014) Gustavo H Dayan et al.   Human Vaccines & Immunotherapeutics

Human Antibody Response toAedes albopictusSalivary Proteins: A Potential Biomarker to Evaluate the Efficacy of Vector Control in an Area of Chikungunya and Dengue Virus Transmission

(2014) Souleymane Doucoure et al.   Biomed Research International

Human Immune Responses to Dengue Virus Infection: Lessons Learned from Prospective Cohort Studies

(2014) Timothy P. Endy   Frontiers in Immunology

Inflammatory and Innate Immune Responses in Dengue Infection

(2013) Vivian Vasconcelos Costa et al.   AMERICAN JOURNAL OF PATHOLOGY

Immunogenicity and Safety of a Recombinant Tetravalent Dengue Vaccine in Children and Adolescents Ages 9–16 Years in Brazil

(2013) Gustavo H. Dayan et al.   AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE

A Shorter Time Interval Between First and Second Dengue Infections Is Associated With Protection From Clinical Illness in a School-based Cohort in Thailand

(2013) Kathryn B. Anderson et al.   JOURNAL OF INFECTIOUS DISEASES

The global distribution and burden of dengue

(2013) Samir Bhatt et al.   NATURE

Safety and Immunogenicity of a Recombinant Tetravalent Dengue Vaccine in 9–16 Year Olds

(2013) Luis Á. Villar et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Safety and immunogenicity of a tetravalent dengue vaccine in healthy children aged 2–11 years in Malaysia: A randomized, placebo-controlled, Phase III study

(2013) Amar-Singh HSS et al.   VACCINE

Safety and immunogenicity of three tetravalent dengue vaccine formulations in healthy adults in the USA

(2013) Gustavo H. Dayan et al.   VACCINE

Persistence of Th1/Tc1 responses one year after tetravalent dengue vaccination in adults and adolescents in Singapore

(2013) Anke Harenberg et al.   Human Vaccines & Immunotherapeutics

Symptomatic Versus Inapparent Outcome in Repeat Dengue Virus Infections Is Influenced by the Time Interval between Infections and Study Year

(2013) Magelda Montoya et al.   PLoS Neglected Tropical Diseases

Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial

(2012) Arunee Sabchareon et al.   LANCET

Immunogenicity and safety of tetravalent dengue vaccine in 2–11 year-olds previously vaccinated against yellow fever: Randomized, controlled, phase II study in Piura, Peru

(2012) Claudio F. Lanata et al.   VACCINE

Broad neutralization of wild-type dengue virus isolates following immunization in monkeys with a tetravalent dengue vaccine based on chimeric Yellow Fever 17D/Dengue viruses

(2012) Veronique Barban et al.   VIROLOGY

Immunogenicity and safety of recombinant tetravalent dengue vaccine (CYD-TDV) in individuals aged 2–45 years

(2012) Yee Sin Leo et al.   Human Vaccines & Immunotherapeutics

Efficacy of a Tetravalent Chimeric Dengue Vaccine (DENVax) in Cynomolgus Macaques

(2011) Jorge E. Osorio et al.   AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE

Priming Effect of Dengue and Yellow Fever Vaccination on the Immunogenicity, Infectivity, and Safety of a Tetravalent Dengue Vaccine in Humans

(2011) Ming Qiao et al.   AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE

Critical issues in dengue vaccine development

(2011) Stephen J. Thomas et al.   CURRENT OPINION IN INFECTIOUS DISEASES

Association of human immune response to Aedes aegypti salivary proteins with dengue disease severity

(2011) C. MACHAIN-WILLIAMS et al.   PARASITE IMMUNOLOGY

Genetic stability of a dengue vaccine based on chimeric yellow fever/dengue viruses

(2011) N. Mantel et al.   VACCINE

Live-attenuated, tetravalent dengue vaccine in children, adolescents and adults in a dengue endemic country: Randomized controlled phase I trial in the Philippines

(2011) Rosario Z. Capeding et al.   VACCINE

From research to phase III: Preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine

(2011) Bruno Guy et al.   VACCINE

Immunological and Viral Determinants of Dengue Severity in Hospitalized Adults in Ha Noi, Viet Nam

(2011) Annette Fox et al.   PLoS Neglected Tropical Diseases

Clinical and Virological Factors Influencing the Performance of a NS1 Antigen-Capture Assay and Potential Use as a Marker of Dengue Disease Severity

(2011) Veasna Duong et al.   PLoS Neglected Tropical Diseases

Phase 2 clinical trial of three formulations of tetravalent live-attenuated dengue vaccine in flavivirus-naïve adults

(2010) Wellington Sun et al.   Human vaccines & immunotherapeutics

Memory CD8+ T cells from naturally acquired primary dengue virus infection are highly cross-reactive

(2010) Heather Friberg et al.   IMMUNOLOGY AND CELL BIOLOGY

A Novel Tetravalent Dengue Vaccine Is Well Tolerated and Immunogenic against All 4 Serotypes inFlavivirus‐Naive Adults

(2010) Dennis Morrison et al.   JOURNAL OF INFECTIOUS DISEASES

Different Innate Signatures Induced in Human Monocyte-derived Dendritic Cells by Wild-Type Dengue 3 Virus, Attenuated but Reactogenic Dengue 3 Vaccine Virus, or Attenuated Nonreactogenic Dengue 1-4 Vaccine Virus Strains

(2010) C. Balas et al.   JOURNAL OF INFECTIOUS DISEASES

Live-attenuated Tetravalent Dengue Vaccine in Dengue-naïve Children, Adolescents, and Adults in Mexico City

(2010) Jorge Poo et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Both Viremia and Cytokine Levels Associate with the Lack of Severe Disease in Secondary Dengue 1 Infection among Adult Chinese Patients

(2010) Yangbo Tang et al.   PLoS One

WHO Working Group on technical specifications for manufacture and evaluation of dengue vaccines, Geneva, Switzerland, 11–12 May 2009

(2010) Dennis Trent et al.   VACCINE

Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses

(2009) Bruno Guy et al.   VACCINE

Recombinant Chimeric Virus with Wild‐Type Dengue 4 Virus Premembrane and Envelope and Virulent Yellow Fever Virus Asibi Backbone Sequences Is Dramatically Attenuated in Nonhuman Primates

(2008) Charles E. McGee et al.   JOURNAL OF INFECTIOUS DISEASES

Substitution of Wild‐Type Yellow Fever Asibi Sequences for 17D Vaccine Sequencesin ChimeriVax–Dengue 4 Does Not Enhance Infection ofAedes aegyptiMosquitoes

(2008) Charles E. McGee et al.   JOURNAL OF INFECTIOUS DISEASES

Cell-mediated immunity induced by chimeric tetravalent dengue vaccine in naive or flavivirus-primed subjects

(2008) Bruno Guy et al.   VACCINE

“Guidelines for the clinical evaluation of dengue vaccines in endemic areas”: Summary of a World Health Organization Technical Consultation

(2008) Robert Edelman et al.   VACCINE

Guidelines for Plaque-Reduction Neutralization Testing of Human Antibodies to Dengue Viruses

(2008) John T. Roehrig et al.   VIRAL IMMUNOLOGY